论文部分内容阅读
目的:观察孟鲁司特联合常规治疗改善过敏性紫癜患儿肾损害的疗效和安全性。方法:过敏性紫癜肾损害患儿67例随机分为观察组(35例)和对照组(32例)。观察组给予孟鲁司特联合常规治疗,对照组仅予常规治疗。连续治疗2个月后,观察两组患儿血清胱抑素C(CysC)、血清β_2-微球蛋白(β_2-MG)、尿转铁蛋白(TRF)、尿微量白蛋白(mAlb)和尿β_2-MG水平变化,比较两组疗效。结果:观察组有效率为94.3%,高于对照组的75.0%(P<0.05)。治疗后,两组患儿尿m Alb、β_2-MG、TRF水平与血β_2-MG、Cys C水平均较治疗前明显下降(P<0.05);除两组血CysC水平差异无统计学意义(P>0.05)外,观察组其他指标水平均明显低于对照组(P<0.05)。结论:孟鲁司特联合常规治疗可明显提高疗效,改善患儿各项实验室指标。
Objective: To observe the efficacy and safety of montelukast combined with conventional treatment to improve renal impairment in children with Henoch-Schonlein purpura. Methods: 67 children with HSP were randomly divided into observation group (35 cases) and control group (32 cases). The observation group was given montelukast in combination with routine treatment, and the control group only conventional treatment. After two months of continuous treatment, the serum cystatin C (CysC), serum β_2-microglobulin (β_2-MG), urinary transferrin (TRF), urine microalbumin (mAlb) β_2-MG level changes, the two groups were compared. Results: The effective rate in the observation group was 94.3%, higher than that in the control group (75.0%, P <0.05). After treatment, the levels of urinary Alb, β_2-MG, TRF and blood β_2-MG and Cys C in both groups were significantly lower than those before treatment (P <0.05), but there was no significant difference except for the level of CysC in the two groups P> 0.05), the other indicators of the observation group were significantly lower than the control group (P <0.05). Conclusion: Montelukast combined with conventional treatment can significantly improve the efficacy and improve the laboratory indicators in children.